考来替泊和氯贝丁酯对IIa型高脂蛋白血症患者血浆脂质及脂蛋白的影响。

Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.

作者信息

Hunninghake D B, Probstfield J L, Crow L O, Isaacson S O

出版信息

Metabolism. 1981 Jun;30(6):605-9. doi: 10.1016/0026-0495(81)90140-2.

Abstract

The effects of 2.0 g of clofibrate and 15, 20 and 30 g of colestipol on plasma lipid and lipoprotein levels were evaluated in adult patients with Type IIa hyperlipoproteinemia. Clofibrate treatment was associated with decreases in 11.0% in plasma cholesterol. 15.2% in LDL cholesterol, 26.1% in triglycerides, and an 11.3% increase in HDL cholesterol. The reductions in total cholesterol with the various doses of colestipol ranged from 11.9 to 17.8% and reductions in LDL cholesterol ranged from 16.1 to 27.3%. Colestipol treatment was not associated with any significant change in HDL cholesterol levels and minor increases in triglycerides. The addition of clofibrate to patients receiving colestipol resulted in a significant increase in HDL cholesterol and a decrease in triglycerides, but no additional reduction in total or LDL cholesterol.

摘要

在患有IIa型高脂蛋白血症的成年患者中，评估了2.0克氯贝丁酯以及15克、20克和30克考来烯胺对血浆脂质和脂蛋白水平的影响。氯贝丁酯治疗使血浆胆固醇降低了11.0%，低密度脂蛋白胆固醇降低了15.2%，甘油三酯降低了26.1%，高密度脂蛋白胆固醇增加了11.3%。不同剂量考来烯胺使总胆固醇降低的幅度在11.9%至17.8%之间，低密度脂蛋白胆固醇降低的幅度在16.1%至27.3%之间。考来烯胺治疗与高密度脂蛋白胆固醇水平的任何显著变化均无关联，甘油三酯仅有小幅升高。在接受考来烯胺治疗的患者中添加氯贝丁酯，导致高密度脂蛋白胆固醇显著增加，甘油三酯降低，但总胆固醇或低密度脂蛋白胆固醇并未进一步降低。